Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461

Blood
Cancer and Leukemia Group B 8461Clara D Bloomfield

Abstract

We investigated the relative prognostic significance of cytogenetics in 635 adult acute myeloid leukemia (AML) patients 60 years of age or older treated on front-line protocols. Classification trees and tree-structured survival analysis (TSSA) were used to identify important cytogenetic groups, and their prognostic significance was then assessed in multivariable analysis (MVA). Overall, 48.5% achieved complete remission (CR); 6.6% survived at 5 years. Complex karyotypes with at least 3 abnormalities (complex > or = 3) and a group including "rare aberrations" predicted lower CR rates (25% and 30%) versus other patients (56%). Compared with complex > or = 3, the odds of CR were significantly higher for noncomplex karyotypes without rare aberrations on MVA. Cytogenetically, complex > or = 5 predicted inferior disease-free survival on TSSA, remaining significant on MVA together with white blood cell count (WBC), sex, and age. For survival, complex > or = 5, rare aberrations, and core-binding factor (CBF) abnormalities were prognostic (P < .001), with 5-year survivals of 0%, 0%, and 19.4%, respectively, and 7.5% for remaining patients. Together with WBC, marrow blasts, sex, and age, the cytogenetic groups remained significant on MVA...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A CaligiuriC D Bloomfield
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W HiddemannT Büchner
May 18, 2001·Best Practice & Research. Clinical Haematology·K MrózekC D Bloomfield
May 30, 2001·Cancer Genetics and Cytogenetics·A V MoormanG J Morgan
Aug 7, 2001·Reviews in Clinical and Experimental Hematology·E Matutes, A Polliack
Apr 18, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·Christiane CharrinXavier Thomas
Jan 11, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Birgit KainzUlrich Jaeger
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Dec 4, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Ramalingam Rathnasabapathy, Jeffrey E Lancet
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S MontotoE Montserrat

❮ Previous
Next ❯

Citations

Sep 9, 2011·Current Treatment Options in Oncology·Gabriela Motyckova, Richard M Stone
Apr 29, 2010·Current Hematologic Malignancy Reports·Ellen K Ritchie, Gail J Roboz
Jul 14, 2012·International Journal of Hematology·Masamitsu Yanada, Tomoki Naoe
Feb 26, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Chang Long LiDavid W Emery
Apr 7, 2010·Proceedings of the National Academy of Sciences of the United States of America·William BlumGuido Marcucci
Apr 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ann-Kathrin EisfeldAlbert de la Chapelle
Sep 1, 2007·Blood Pressure Monitoring·John N AmooreAlan Murray
Jan 15, 2010·Current Opinion in Hematology·Brian L McClune, Daniel J Weisdorf
Dec 6, 2012·Leukemia Research and Treatment·Geoffrey Brown, Philip Hughes
Aug 16, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Irum KhanJonathan D Licht
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria R BaerRichard A Larson
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
Dec 24, 2010·Drugs·Lily P H Yang, Caroline M Perry
Jun 2, 2012·Clinical Medicine Insights. Oncology·Tara L Lin, M Yair Levy
May 23, 2014·Clinical Interventions in Aging·Ming Y Lim, Katarzyna Jamieson
May 20, 2014·Current Hematologic Malignancy Reports·James M Foran
Mar 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaomeng HuangGuido Marcucci
Mar 1, 2014·Leukemia & Lymphoma·Ashkan Emadi, Judith E Karp
Nov 26, 2010·Expert Review of Hematology·Karen W L Yee, Armand Keating

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.